U.S. Senate Republicans have launched a formal investigation into the manufacturers of chemical abortion drugs, demanding answers from the Food and Drug Administration (FDA) about the safety, marketing, and distribution of mifepristone — the primary drug used in medication abortions.
In a letter sent to FDA Commissioner Marty Makary on March 25, 2026, Republican senators cited mounting evidence of serious complications linked to the abortion pill, including life-threatening bleeding, infection, and incomplete abortions. They are pressing the agency to explain why critical safety standards were weakened during the Biden administration, particularly the decision to allow the drug to be mailed without in-person medical oversight.
The probe comes as chemical abortions now account for more than 60% of all abortions in the United States. Pro-life advocates argue that the FDA has failed to adequately protect women and has prioritized access over safety, especially after the Supreme Court’s 2022 Dobbs decision returned abortion regulation to the states. Senate Republicans are demanding detailed records on adverse event reports, clinical trial data, and the FDA’s decision-making process.
They warn that the current regulatory framework puts women at risk and enables the circumvention of state laws designed to protect unborn children. This investigation represents a significant escalation in congressional oversight of the abortion industry and the FDA’s handling of mifepristone. The move aligns with the Trump administration’s broader commitment to reining in federal agencies and restoring common-sense protections for both mothers and their unborn children.